GPRASP1 and prostate carcinoma: Figure 1 shows that in our GASP-1 ELISA, there is a 5-fold difference in serum GASP-1 levels between BPH and prostate cancer patients. A 20-fold difference in serum GASP-1 levels between healthy individuals and prostate cancer patients was also found. To confirm the statistical significance of our results, we performed a one-way ANOVA test, and it yielded an F-statistic of 4.5038 and a p value of 0.01948. Since the p value is less than 0.05, we conclude that there is a statistically significant difference in GASP-1 levels between the healthy, BPH, and prostate cancer groups.